Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign
Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign
复制标题
英国 2023 年秋季 COVID-19 加强疫苗接种活动中的疫苗表现各异
DOI：
10.1016/s0140-6736(24)00316-7
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Shawe-Taylor M
中科院分区：
文献类型：
--
作者：
Shawe-Taylor M
2023年12月13日，世卫组织COVID-19疫苗成分技术咨询小组（TAG-CO-VAC）重申了他们自2023年5月起的指导意见1，建议更新疫苗，以更好地诱导针对Omicron XBB的中和抗体。1血统和它的后代在当时的流通。TAG-CO-VAC建议使用单价XBB。1或后代血统（例如，XBB. 1.5），并特别建议不要将2019年首次发现的祖先指数病毒纳入疫苗中。在美国和日本等国家，2023年秋季的加强免疫计划中没有使用包含较老的Omicron谱系和指示病毒的二价疫苗。相比之下，在英国，疫苗接种和免疫联合委员会（JCVI）采取了务实的方法2，并建议除了新的单价XBB疫苗外，继续使用以前的二价mRNA疫苗库存。1.5-编码mRNA疫苗，其基础是两者都在2023年年中显示出有效性-尽管之前的二价疫苗编码病毒的刺突蛋白，最后一次传播是在2022年年中和2020年初（附录第3页）.自首次作出这些决定以来，SARS-CoV-2已经发生了很大的变化：在2023年的过程中，XBB谱系在其刺突蛋白中积累了几个突变，这些突变已被证明会逐渐降低来自感染和接种疫苗个体的血清的中和能力。3值得注意的是，omicron，BA. 2.86，在2023年8月被发现，虽然它是BA的后代。2谱系，其序列与XBB的差异大于BA。1来自delta（B. 1.617. 2)当BA 1首次出现（附录第3页）。BA. 2.86一直是欧洲的主流血统
On Dec 13, 2023, WHO’s Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) reiterated their guidance1 from May, 2023, recommending updating vaccines to better induce neutralising antibodies against the omicron XBB. 1 lineage and its descendants that were in circulation at the time. TAG-CO-VAC suggested the use of monovalent XBB. 1 or descendant lineage (eg, XBB. 1.5), and specifically recommended moving away from the inclusion of the ancestral index virus, first detected in 2019, in vaccines. In countries such as the USA and Japan, bivalent vaccines incorporating older omicron lineages and the index virus were not used for the autumn 2023 booster programmes. By contrast, in the UK, the Joint Committee on Vaccination and Immunisations (JCVI) adopted a pragmatic approach2 and recommended the continued use of stocks of previous bivalent mRNA vaccines in addition to the newer monovalent XBB. 1.5-encoding mRNA vaccines, on the basis that both showed efficacy during mid-2023—despite the previous bivalent vaccines encoding the Spike protein of viruses that last circulated in mid-2022 and early 2020 (appendix p 3).SARS-CoV-2 has evolved considerably since these decisions were first made: over the course of 2023, the XBB lineage accumulated several mutations in its Spike protein that have been shown to incrementally decrease the neutralising capacity of serum from infected and vaccinated individuals. 3 Notably, a new lineage of omicron, BA. 2.86, was detected in August, 2023, and although it is a descendant of the BA. 2 lineage, its sequence is more divergent from XBB than BA. 1 was from delta (B. 1.617. 2) when BA. 1 first appeared (appendix p 3). BA. 2.86 has been the dominant lineage in Europe
影响因子：
105.7
作者：
Hippisley-Cox, Julia;Khunti, Kamlesh;Sheikh, Aziz;Nguyen-Van-Tam, Jonathan S.;Coupland, Carol A. C.
通讯作者：
Coupland, Carol A. C.